Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.56 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | BCHE | P06276 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4559188 | 0.90 | HTT (0.53) | HTTALDH1A1BCHETSHR | |
| SCHEMBL19884755 | 0.84 | HTT (0.55) | GAALMNAKDM4EHPGDDUSP3 | |
| SCHEMBL3459488 | 0.83 | HTT (0.57) | GAALMNAKDM4EHPGDDUSP3 | |
| SCHEMBL2347336 | 0.81 | GAA (0.70) | GAALMNAKDM4EHPGDDUSP3 | |
| SCHEMBL13655375 | 0.81 | LMNA (0.84) | GAALMNAKDM4EHPGDDUSP3 | |
| SCHEMBL17471147 | 0.81 | LMNA (0.52) | GAALMNAKDM4EHPGDDUSP3 | |
| SCHEMBL76649 | 0.80 | GAA (0.68) | GAALMNAKDM4EHPGDDUSP3 | |
| SCHEMBL11742767 | 0.78 | LMNA (0.69) | GAALMNAKDM4EHPGDDUSP3 | |
| Hydrochloric Acid SCHEMBL5658003 | 0.78 | GAA (0.66) | GAALMNAKDM4EHPGDDUSP3 | |
| SCHEMBL8762651 | 0.78 | GAA (0.66) | GAALMNAKDM4EHPGDDUSP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137549-A1 | Novel compounds useful for the treatment of degenerative & inflamatory diseases | GALAPAGOS NV (BE) | 2009-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137549-A1 | Novel compounds useful for the treatment of degenerative & inflamatory diseases | PDE4A, PDE7B, PDE4B | GAA 335/4885LMNA 1062/4885KDM4E 2692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.